SynthesisJournal of the ASEAN Federation of Endocrine Societies2026
Liver Enzyme Biomarkers Before or in Early Pregnancy as Predictors for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Synthesis in Journal of the ASEAN Federation of Endocrine Societies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver enzymes may reflect early metabolic disturbances and insulin resistance preceding gestational diabetes mellitus (GDM). This systematic review and meta-analysis evaluated whether liver enzyme biomarkers measured before or in early pregnancy are associated with subsequent development of GDM. Methodology: PubMed, Cochrane, EBSCOHost, and SCOPUS databases were searched through May 2025 for observational studies or trials assessing pre- or early pregnancy liver enzymes in relation to GDM development. Pooled mean differences (MD) and odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model. Risk of bias was assessed using RoB 2.0 and ROBINS-E; certainty of evidence was evaluated using GRADE. Results: Twenty-seven studies were included in the analyses. GDM was associated with higher AST (MD 0.97 U/L; OR 1.42), ALT (MD 2.38 U/L; OR 1.69), GGT (MD 3.77 U/L; OR 2.57), and hepatic steatosis index (HSI) (MD 2.82; OR 2.19). ALP showed no significant mean difference but an elevated GDM risk (OR 1.47). Substantial heterogeneity was observed with very low certainty of evidence across outcomes. Conclusion: Elevated liver enzymes, especially GGT and HSI, are associated with increased GDM risk at a population level. However, high heterogeneity and very low certainty of evidence limit current clinical applicability, warranting further prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.